E-CLAD UK Long-term
After a double lung transplant, the body can sometimes begin to reject the new lungs. This condition is called chronic lung allograft dysfunction. An earlier clinical trial, called E-CLAD UK, tested a light-based blood treatment called extracorporeal photopheresis (ECP) to help calm the immune system. While that study followed patients for 24 weeks, doctors need to know how people do over a longer time. This follow-up study follows participants for up to two years. It is open only to people who completed the first E-CLAD UK trial. Taking part does not require any new medicines or hospital visits. Instead, participants fill out short quality-of-life surveys online and allow researchers to review their NHS medical records. Up to 20 people may also do a phone or video interview. This information helps researchers understand how the treatment works long term and whether it offers good value for the NHS.
At a glance
What is this study about?
Having a lung transplant can save lives, but over time, the body's immune system may treat the new lungs as foreign and begin to attack them. Doctors call this chronic lung allograft dysfunction, or CLAD. It causes long-term breathing problems and can damage the transplanted lungs. To help manage this, doctors have been researching a therapy called extracorporeal photopheresis (ECP). This treatment takes a small amount of blood, treats it with a medicine activated by ultraviolet light, and returns it to the body to help settle the immune response.
An earlier study called E-CLAD UK tested this therapy over 24 weeks. However, lung transplant care is a long journey, and doctors need to see how patients get on over a much longer period. This follow-up study tracks participants for up to two years to learn how their breathing, general health, and daily well-being hold up over time.
This research is important because it looks at the bigger picture of life after transplant treatment. By tracking participants' health and NHS visits, researchers can see whether the benefits last and if the therapy is cost-effective for the NHS. The findings will help doctors provide the best possible care for future transplant patients.
Key takeaways
- A follow-up study for people who finished the original E-CLAD UK clinical trial.
- Tracks health, quality of life, and NHS care use over two years.
- Involves filling out short online questionnaires at home and checking medical records.
- No new study medications, blood tests, or extra hospital visits are required.
- Helps doctors understand long-term outcomes to improve future transplant care.
Who may be eligible?
This study is only open to adults who took part in and fully finished the earlier E-CLAD UK clinical trial. Because this is a long-term follow-up study, researchers can only include people whose health was already tracked in the original trial.
To take part, you must be able to understand the study information and give your written consent. Healthy volunteers and people who did not take part in the original study cannot join.
If you agreed to join the first E-CLAD UK trial but were later found not to meet all the rules, or if you had to leave before it finished, you will not be able to join this follow-up study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I had a double lung transplant.
- I took part in and completed the original E-CLAD UK clinical trial.
- I am an adult aged 18 or older.
- I can give written informed consent to take part.
- I am willing to complete brief questionnaires online over the next two years.
What does participation involve?
Taking part in this study is designed to fit easily into your normal life. There are no extra clinic visits, blood tests, or study medications. Over a two-year period, you will be asked to fill in two short questionnaires at up to three different times. These surveys ask about your daily activities, feelings, and general quality of life. Each takes about ten minutes and can be completed online using a mobile phone, tablet, or computer.
Researchers will also look at your routine NHS medical records at around 52 weeks (one year) and 104 weeks (two years). They will check your health progress and see how often you have needed hospital or clinic care. In addition, around 20 participants may be invited to take part in an optional one-hour chat by phone or video call to share their personal thoughts on their care.
Potential risks and benefits
Locations (5)
- The Newcastle upon Tyne Hospitals NHS Foundation TrustCity onlyNewcastle upon Tyne, England
- Royal Papworth Hospital NHS Foundation TrustCity onlyCambridge, England
- University Hospitals Birmingham NHS Foundation TrustCity onlyBirmingham, England
- Manchester University NHS Foundation TrustCity onlyManchester, England
- Guy's and St Thomas' NHS Foundation TrustCity onlyLondon, England
Common questions
Will I need to take any new medicines for this study?
No. This is a follow-up study that collects information through surveys and medical notes. You will not receive any new treatments.
Do I have to travel to hospital appointments for this?
No. The questionnaires can be completed at home on your phone, tablet, or computer, so no extra travel is needed.
Who is running and funding this research?
The study is run by the Newcastle Clinical Trials Unit in the UK and is funded by a healthcare company called Therakos.
What happens if I don't want to do the interview?
The one-hour interview is completely optional and only involves up to 20 people. You can still take part in the survey part of the study even if you do not do an interview.
Can I leave the study if I change my mind?
Yes. You are free to withdraw at any point. Deciding to leave will never affect your routine NHS treatment or your relationship with your healthcare team.
How to find out more
- Trial Manager
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.